Viral load responses to HAART is an independent predictor of a new AIDS event in late stage HIV infected patients: prospective cohort study

被引:0
作者
Powel Kazanjian
Wei Wei
Morton Brown
Tejal Gandhi
Kamal Amin
机构
[1] University of Michigan Health System,Department of Internal Medicine
[2] University of Michigan School of Public Health,Department of Epidemiology
来源
Journal of Translational Medicine | / 3卷
关键词
Viral Load; CD4; HAART; AIDS;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 64 条
[1]  
Palella F(1998)Declining morbidity and mortality among patients with advanced HIV infection N Engl J Med 338 853-60
[2]  
Delaney K(1999)AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy JAMA 282 2220-6
[3]  
Moorman A(2003)Mortality and progression to AIDS after starting highly active antiretroviral therapy AIDS 17 2227-36
[4]  
Ledergerber B(2002)Prognosis of HIV-1 Infected patients starting Highly Active Antiretroviral Therapy: A Collaborative Analysis of Prospective Studies Lancet 360 119-29
[5]  
Egger B(2003)Improved Outcomes with Earlier Initiation of Highly Active Antiretroviral Therapy among Human Immunodeficiency Virus-Infected Patients who Achieve Durable Virologic Suppression: Longer Follow-Up of an Observational Cohort Study J Infect Dis 188 1659-65
[6]  
Erard V(2003)Prognostic value of baseline HIB type 1 DNA measurement for disease progression in patients receiving nucleoside therapy J Infect Dis 187 144-8
[7]  
Van Sighem AI(2003)Higher baseline levels of plasma HIV type 1 RNA are associated with increased mortality after initiation of triple drug antiretroviral therapy J Infect Dis 188 1421-5
[8]  
van de Wiel MA(1997)AIDS prognosis based on HIV-1 RNA, CD4+ T cell count and function: markers with reciprocal predictive value over time after seroconversion AIDS 11 1799-806
[9]  
Ghani A(2004)Prognostic value of plasma HIV RNA among highly active antiretroviral users AIDS 18 2419-23
[10]  
Egger M(2004)Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy J Acquir Immune Defic Syndr 37 1147-54